Where does Myriad Women's Health, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Myriad Women's Health, Inc. ranks #10,696 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Myriad Women's Health, Inc. hold?

Myriad Women's Health, Inc. holds 29 US utility patents granted between 2019 and 2025, spanning 14 technology areas.

What is Myriad Women's Health, Inc.'s Innovation Score?

Myriad Women's Health, Inc. has an Innovation Score of 57.1 out of 100 (top 5% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Myriad Women's Health, Inc.'s patent grant rate increasing or decreasing?

Myriad Women's Health, Inc.'s recent grant velocity is +1800% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Myriad Women's Health, Inc.'s patents?

Myriad Women's Health, Inc.'s patents average 20.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Myriad Women's Health, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Myriad Women's Health, Inc.

Q: What technology areas does Myriad Women's Health, Inc. focus on?

Myriad Women's Health, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 21 patents. Grants appear in 14 CPC subclasses total.

USPTO PatentsView assignee record - 29 granted patents across 14 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Myriad ranks #10,696 of 50,000 tracked US assignees by granted-patent volume, with 29 patents across 14 technology areas.

#10,696
of 50,000 US assignees by volume: Top 5%
by Innovation Score (57.1/100): 20.2
avg claims per patent: +1800%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10696 · US Corporation #10,696 · 29 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 29 grants
UPPER-Q #10,696/50,000
PHOTO-FINISH Moraine
CPC-FOCUS C12Q · 14 areas
INNOV-PAR 57.1/100
CLAIMS-DENSE 20.2 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +1800% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Moraine Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Black Diamond Oilfie… · near

57
Brightview · near

57
Chongqing BOE Displa… · near

57
Eltek S p a · near

57
Myriad Women's Health · this assignee

57
3D Lighting Innovati… · lowest

7

What this shows Myriad Women's Health, Inc. stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-FOCUS, INNOV-PAR, CLAIMS-DENSE, TYPE-USCORP, VEL-SURGE, BOOK-FULL. Volume places it #10,696 of 50,000; Innovation Score 57.1/100 sits in the top 5% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Moraine Corporation (±0 grants).

Portfolio overview

Myriad Women's Health, Inc. has been granted 29 US utility patents between 2019 and 2025, placing Myriad Women's Health, Inc. at #10,696 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.2 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Myriad Women's Health, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Myriad sits between Moraine Corporation (29 patents, rank #10,691) and Nexrf Corp. (29 patents, rank #10,699) - the closest US assignees by grant volume. The composite Innovation Score of 57.1/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 19 grants, compared with 1 in the 2015–2019 window, a +1800% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Myriad Women's Health, Inc.'s 20.2 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 14 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Moraine

29
Moshun

29
Movellus Circuits

29
Myriad Genetics

29
Nanoport Technolo…

29
National Agricult…

29
NEC Lighting

29
Nexrf

29
Myriad Women's He… ◀

29

What this shows Myriad holds 29 patents at rank #10,695, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Myriad

By rank, the assignees closest to #10,695 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Myriad's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Myriad, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (57 here).

Black Diamond Oilfield Rentals Llc 57 Brightview Technologies, Inc. 57 Chongqing BOE Display Technology Co., Ltd. 57 Eltek S.p.a. 57

Myriad's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

57 Top 5% higher than 95% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Myriad Women's Health, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	3.4%
2020	2	6.9%
2021	2	6.9%
2022	3	10.3%
2023	3	10.3%
2024	9	31.0%
2025partial year	9	31.0%

Which technologies does Myriad Women's Health, Inc. patent most?

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 21

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 13

G16B - BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY 7

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 7

B01L - CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE 3

F04B - POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS 2

C40B - COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES 2

C12Y - ENZYMES 1

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 1

G06F - ELECTRIC DIGITAL DATA PROCESSING 1

G08B - SIGNALLING OR CALLING SYSTEMS; ORDER TELEGRAPHS; ALARM SYSTEMS 1

G06Q - INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR 1

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 1

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 1

Top 14 of 14 technology areas

Where it ranks

Overall rank by patents

#10,696

of 50,000 tracked assignees

Innovation Score

57.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.